Good morning, everyone. Welcome to the 2026 Jefferies Global Healthcare Conference. This morning, we're very pleased to have Mark Baum, CEO of Harrow. Thank you very much.
Thank you. I want to thank our friends at Jefferies. We really appreciate this audience. I know it's 8:00 A.M. If you're from the States, it's even earlier. Many of you haven't had your second or third cups of coffee, but you're investors, so I'm going to try and stimulate you in a different way by talking about three value drivers for Harrow. The first is the growth that we've delivered and that we are delivering. The second is the operating leverage that's now showing up in our business. The third is the opportunity to really accelerate our growth in the coming years. Towards the end of the presentation, I actually have a special surprise that I'm going to provide to the audience, so stay tuned. Harrow's in the ophthalmic pharmaceutical business.
We focus on the U.S. market. We now have the broadest portfolio, the largest portfolio of prescription eye care products for the U.S. market. There are three core brands that we're going to talk about today that are the primary drivers of our growth, and they're all in early stages of their growth. Then finally, we've built a commercial platform, bought, it's paid for, it is deployed, and it is structured for us to actually add additional products onto for the same exact call point that these teams call on day in and day out. Here's a look at our financials.
As you can see, we've grown nicely over the last five years. We have a five-year revenue CAGR of better than 40%, a five-year adjusted EBITDA CAGR of better than 60%. We've guided that we'll do between $350 million and $365 million this year.
The midpoint is $357.5 million, and that's up from $272.3 million last year. We've guided that in the fourth quarter, we'll do better than $33 million in adjusted EBITDA, and that's up from the $21.2 million that we recently reported. The third quarter of this year was a record quarter for Harrow. We did better than $99 million, just a whisker under $100 million in revenue, $83.5 million of which was branded revenue with a gross margin profile of nearly 80%. We have about $75 million in cash in the bank at the end of the period. We do have $300 million in unsecured notes that bear an 8 and 5/8% coupon that are due in about four years. Let's jump into those three pillars of growth that I discussed.
The first is the growth that we have delivered and that we are intending to continue to deliver. Let's talk about those three products. The first is VEVYE. VEVYE is a dry eye disease product, and in the third quarter, it did nearly $40 million in revenue. That was 75% growth in the third quarter over the prior year's third quarter. Prescriptions for VEVYE were up 83% year-over-year. IHEEZO is a unique patented ocular anesthetic that did over $25 million in revenue for the quarter. That was 15% growth in revenue with unit demands up 21%.
I am going to drill down a little bit more into IHEEZO specifically in a few minutes, because the performance of that product was actually better, I think, than these numbers even indicate. Then finally, TRIESENCE is an injectable steroid. It is used in ocular surgery.
That is the primary market, and it is growing rapidly. It did better than $10 million in revenue for the quarterly period, growing beautifully, 186% growth in revenue with unit demand up 110%. In the aggregate, those three products make up about $75 million of our revenue. That is 76% of our total and 91% of our branded revenue. Let's look a little bit deeper at the specific products. VEVYE, in particular, serves the dry eye market. It is a very large market in the U.S. More than 38 million Americans suffer from dry eye symptoms. However, only a little over 1 million patients are on prescription therapy, but the category is growing nicely. In fact, it has grown at better than 20% a year for the past two years. How do we participate in the market, that growing market?
With VEVYE, which is the only water-free cyclosporine, which is an anti-inflammatory, in the dry eye disease category. It does not contain water. What does that mean? It has a unique vehicle that uniquely is able to deliver cyclosporine more efficiently than any other vehicle that we know of. In fact, it delivers about 22x the amount of cyclosporine to the site and source of inflammation than does the vehicle in, for example, RESTASIS, which may be a product that you are familiar with.
The drug works very quickly, in as little as 15 days. If you have ever put it on your eye, you know that it feels good when you put it on your eye, which is different than many of the other competing products in the category that burn or sting or can cause dysgeusia, give you a bad taste in your mouth.
We have good IP out into the late 2030s, 2039. In terms of the performance of the product, as I said, record revenues in the third quarter. We did just under $40 million in revenue. Prescription growth up 83%. Sequential quarterly revenue growth of 35%. We have made an investment in this program because we really believe in it. We have increased the size of the sales organization from the beginning of the year to the present time about threefold, and we continue to get more and more coverage for VEVYE. In fact, on January 1st, we have 10.7 million new commercial lives that we will have access to. When we evaluate a product like VEVYE, we really look at three main factors to think about the health of the brand.
The first is net pricing, the second is total prescriptions, and the third is insurance coverage, and the ratio of patients that are paying cash versus seeking insurance for their prescriptions. In all three of those categories, total prescriptions, net pricing, and insurance access, VEVYE is improving and on the rise. The second of our products that I want to talk about is IHEEZO, which is a patented reimbursable topical anesthetic for the U.S. market, and uniquely, it is the only reimbursable product in the U.S. eye care market. If you are going to poke on the eye, inject something into the eye, or cut on the eye, you need to anesthetize the eye, obviously. IHEEZO, as I said, is the only product currently in the market that is reimbursable. It has a product-specific permanent J-code.
Now, I mentioned that unit demand was up 21%, and that may be a little bit of a misnomer in terms of the actual performance of the product this year. I want to elaborate a little bit more on what I mean. At the beginning of this year, we sold IHEEZO into two markets, two distinct customers. One was the cataract surgery market, where we sold to the cataract surgeons. It was used to anesthetize the eye for cataract surgeries. The second market was for intravitreal injections, whether you are injecting EYLEA, LUCENTIS, VABYSMO, we really did not care what you were injecting as long as you anesthetize the eye with IHEEZO. Both of those markets were being served by IHEEZO.
However, at the end of the first quarter of 2026, we lost our pass-through status, and so the entire cataract surgery market, that outreach to the cataract surgeon completely went away. What I think is interesting and telling about the health of the brand is that despite losing more than 20% of the unit demand for IHEEZO after we lost pass-through, we still managed in the third quarter to have 21% growth in that franchise in terms of unit demand in the third quarter of 2026 versus 2025. What does that all mean for the future if you are an investor in Harrow? It means a couple of things, because on July 1st, we were able to actually see a 25% increase in our net price, and we are in the fourth quarter.
The fourth quarter is historically the strongest quarter for this product. I believe it will be the strongest quarter in the history of our selling IHEEZO. It is also going to be buttressed, our sales efforts that is, by some recent data that we invested in called the QUELL study, which demonstrated that if you use IHEEZO as opposed to standard of care anesthesia, patients immediately after an injection of lidocaine versus our topical anesthetic have essentially the same level of pain, two out of five. However, after that fourth hour and up to 24 hours, if you use the topical anesthetic as opposed to the standard of care, which is an injection of lidocaine, you actually have less pain, less ocular surface damage, and fewer adverse events. So great data to help us increase the unit volumes of IHEEZO going forward.
Now, TRIESENCE has been a great story for us, and it is now starting to show in the third quarter. Recall that this is an injectable steroid. It was purchased by us from Novartis, and at the time that we purchased it really was not available for most of the prior five years. It was not in stock for ophthalmologists to get access to. We acquired it, we fixed the supply chain, we actually fixed the coding and reimbursement for the product, and we began to sell the product on the entirety of the label, and now you see the demand showing up. We did have a record quarter for TRIESENCE, better than $10 million in revenue, but it is a big market opportunity, not only for surgical inflammation, but also other retina indications as well that are in office.
The product has tremendous coverage, better than 95% coverage, and for the patient, a very low out-of-pocket at around $38 out of pocket. We really believe strongly in TRIESENCE, and we are investing in TRIESENCE, this brand. We have a cataract surgery phase IV study that is going to read out in the first half of 2027, and we have invested in a next-generation version of this product that we are going to file, hopefully we will file an NDA in 2027 and launch in 2028 or early 2029.
Big market opportunity, it is a high-trust product, great reimbursement, low out-of-pocket. We believe strongly in what we are doing for this community with TRIESENCE. Operating leverage. We have a great platform that we have built, but now, interestingly, our revenues are growing faster than our cost structure, and this is what I mean by operating leverage. We have four commercial teams.
We have an ocular surface team that is focused on selling VEVYE. We have a retina team that is focused on selling IHEEZO, and then a surgical team that is focused on our TRIESENCE brand. We also have a fourth team called Access Plus that only focuses on compounded medications. Here is what I mean by operating leverage. If you look at SG&A as a percentage of revenue, in the first half of this year, it was 84%. However, in the third quarter, it went down to 54%.
Third-quarter revenue rose 41%, yet our cost structure did not markedly increase, and that is shown on this bar chart on this next slide. You see that we had flat SG&A from Q2 to Q3. We also had an increase in revenue of about $28 million, $22 million of which went to the profit line. So, 78% of that was converted.
We do not expect, as we continue to grow, to see that cost structure increase, not nearly at the same rate as our revenues are expected to increase, and that is what we mean by operating leverage now showing up in the business model. In fact, over the coming quarters, those percentages might even rise. We have these core products. They are a significant portion of our branded revenue. We have this commercial infrastructure that we have invested in, we have built, we have deployed, and now we are set to actually accelerate our growth.
We have new products that we intend to launch in growing categories over the coming years. In fact, we will have one product launch every year into 2030, and each of those products will fit within the existing commercial teams that we have already deployed. That should not only accelerate our growth, but also increase this operating leverage concept.
This is what I mean by new products each year into 2030. I mentioned the ocular surface team, they focus on selling VEVYE, but we recently acquired TYRVAYA from Viatris, and in the fourth quarter, it is now producing revenue for Harrow. Next year, it will produce more than $30 million of revenue for Harrow, once again, being sold by that same ocular surface disease team that is focused on VEVYE. No additional infrastructure cost, SG&A costs for that. On the retina side of things, that team is focused on IHEEZO. We have already launched BYOOVIZ, which is our LUCENTIS reference biosimilar that launched July 1st. It is having a pretty strong fourth quarter, by the way.
Next year, we intend to launch OPUVIZ, which is our EYLEA 2 mg biosimilar that will also be sold through the retina team to the same call point that they call on day in and day out. Then finally, our surgical team that focuses on TRIESENCE is launching BYQLOVI this quarter, and will launch, hopefully in 2028, G-MELT, which I am going to talk about shortly, and then, of course, our next-generation version of TRIESENCE. You see that the teams are there, they are calling on these doctors, and we can add to their bags without disrupting their ability to be effective with their primary products. This is just an illustration of what I meant by products that are delivering revenue that is currently effective.
TYRVAYA is a dry eye disease nasal spray, and that is being sold by our ocular surface team, BYOOVIZ and OPUVIZ, as I said, through our retina team. Now, I am going to talk to you about G-MELT, which is an exciting product that we are going to hopefully file an NDA on in the coming weeks. G-MELT began with a phone call that I received from a cataract surgeon over 10 years ago who was interested in sedating cataract surgery patients without IVs and without opioids. Believe it or not, in the U.S., nine out of 10 of these cataract surgeries involve the administration of fentanyl in order to sedate patients for cataract surgery. His idea was to, as I said, eliminate the IV and eliminate the opioids. So, we built a compounded product for him.
We began to sell it into the market, and it started with one doctor, and that one became 10, and the 10 became 100, and all of a sudden, we had over 800 institutions using the compounded version of the product. Then dermatologists called us, dentists called us, ENTs called us. Other specialties and subspecialties were interested in sedating their patients using this compounded version of what we are going to talk about, which is called the G-MELT. We decided to seek FDA approval for it and run a traditional regulatory program for, as I said, what we now call G-MELT. In the next couple of weeks, we intend to file an NDA on this product, and hopefully we will have a label to sedate patients for cataract surgery in the U.S. market.
Then over the coming years, we can invest in expanding the label for other opportunities and indications, because the need for procedural sedation medicaments is significant. It is more than 100 million annual procedures in the U.S. market alone, but we are starting off with the cataract surgery. I did promise you a special gift. While I was here in London, yesterday we arrived, I went out to visit our partner, which is Catalent.
We deliver this sublingual sedation medication, the G-MELT, using a technology that they have called Zydis. You can imagine if you are a cataract surgery patient, you are going in for the procedure, you are worried about your vision post-procedure, you are worried about maybe getting an IV, you may be worried about getting an opioid. This is an opportunity to reduce or eliminate those exposures.
Our friends at Catalent actually gave us some samples of the Zydis technology. These do not have active ingredient in them, but I am going to ask Andrew to pass them around. They are actually breath mints, and you can put them under your tongue and experience what it feels like to have this Zydis technology under your tongue, and you can see how fast the tablet melts away. It is literally in a matter of three to five seconds. We are really excited about the G-MELT, we are excited to file the NDA, and we are really excited to offer our 800-plus institutional customers that currently buy the compounded version of the product to have now an FDA-approved, hopefully reimbursable version of this product.
The catalysts for Harrow are significant this year and in 2028, 2029, and 2030 as we continue to launch more products and get operating leverage from our commercial infrastructure and hopefully accelerate our growth. We are going to have an investor day in New York in the spring. We hope to talk about our TRIESENCE data then. In January, we are actually going to discuss the full results of our QUELL study, and a lot of interesting things happening next year, I think, that will act as catalysts for the business, and not the least of which is having our PDUFA date for the G-MELT.
I hope you will all agree that we have delivered growth, we continue to deliver growth, we are seeing operating leverage show up in our business, and we do have the opportunity to meaningfully accelerate our growth as we launch additional products in growing categories through our commercial infrastructure each year through 2030. Finally, I will just say that there was a quote in my last stockholder letter. I said, "I saw a disconnect between the stock's performance and the value that the team has worked so hard to create."
I do want to say that for us, for our team, we are focused on consistent operational execution. If you are a shareholder in Harrow, know that the entire Harrow family is focused on operational execution, and we believe that is the only remedy, really, for healing this disconnect, which we intend to do. Thank you very much.